Darrell White, MD
Ophthalmology · Westlake, OHNPI 1417918517
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 31.9% of the total. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 809 payments — averaging $725.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$187K
- Sun Pharmaceutical Industries Inc.$103K
- Tarsus Pharmaceuticals, Inc.$85K
- Oyster Point Pharma, Inc.$61K
- Eyevance Pharmaceuticals LLC$34K
- AbbVie$31K
- plus $85K from 23 others
Across 13 payments — averaging $1770.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$20K
- Oyster Point Pharma, Inc.$3K
- Shire North American Group Inc$430
What the payments were for
- Consulting fees$200,57634%
- Speaking & faculty fees$328,58056%
- Travel & lodging$31,9885%
- Food & beverage$25,6054%
- Education$1570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 183 | $187,007 |
| Sun Pharmaceutical Industries Inc. | 154 | $103,256 |
| Tarsus Pharmaceuticals, Inc. | 72 | $85,301 |
| Oyster Point Pharma, Inc. | 73 | $60,512 |
| Eyevance Pharmaceuticals LLC | 38 | $34,328 |
| AbbVie(2 entities) | 95 | $31,103 |
| Thea Pharma Inc. | 9 | $19,099 |
| Nordic Pharma, Inc. | 2 | $14,104 |
| Shire North American Group Inc | 14 | $9,997 |
| Tearlab Corp | 10 | $8,919 |
| Novartis | 39 | $6,488 |
| Kala Pharmaceuticals, Inc. | 20 | $6,250 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $6,139 |
| Omeros Corporation | 4 | $3,555 |
| Sight Sciences, Inc. | 5 | $3,348 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $3,011 |
| Eyepoint US, Inc. | 7 | $2,517 |
| Alcon | 25 | $626 |
| Quidel Corporation | 8 | $521 |
| Dompe US, Inc. | 7 | $176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $142 |
| Ocular Therapeutix, Inc. | 4 | $140 |
| Biotissue Holdings Inc. | 5 | $111 |
| Carl Zeiss Meditec USA, Inc. | 2 | $98 |
| Amgen(2 entities) | 3 | $50 |
| Rayner Intraocular Lenses Limited | 3 | $49 |
| Harrow Eye, LLC | 1 | $37 |
| Gilead | 1 | $22 |
| NEW World Medical,inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$157,160
- XIIDRA$148,855
- CEQUA$76,920
- XDEMVY$64,257
- TYRVAYA$59,110
- BROMSITE$24,377
- Flarex$15,584
- Lacrifill$14,104
- Zerviate$10,620
- RESTASIS$10,590
- TearLab Osmolarity System$8,772
- Tobradex ST$7,853
- RESTASIS MULTIDOSE$5,863
- EYSUVIS$5,530
- enVista MX60 IOL$5,396
- Tecnis IOL$5,063
- AzaSite$3,750
- OMIDRIA$3,500
- ENVISTA ENVY IOL$3,400
- Crystalens Accommodating IOL (AT-52AO)$3,400
How this compares
$586,905 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 292 | $431,423 |
| XiidraLifitegrast | 151 | $206,006 |
| XdemvyLotilaner | 51 | $98,127 |
| Cyclosporine | 118 | $77,255 |
| MieboPerfluorohexyloctane/Pf | 82 | $71,637 |
| LumiganBimatoprost | 32 | $22,299 |
| Loteprednol Etabonate | 142 | $20,117 |
| ProlensaBromfenac Sodium | 44 | $15,832 |
| CequaCyclosporine | 21 | $14,639 |
| Bromfenac Sodium | 77 | $11,463 |
| TyrvayaVarenicline Tartrate | 13 | $8,578 |
| Alphagan PBrimonidine Tartrate | 36 | $7,547 |
| Lotemax SmLoteprednol Etabonate | 21 | $5,300 |
| Prednisolone Acetate | 162 | $4,849 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 20 | $4,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $31,103 | $461,270360 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $187,007 | $277,643233 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $85,301 | $98,12751 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm | $3,011 | $41,250207 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $103,256 | $14,63921 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $60,512 | $8,57813 claims |
| Eyevance Pharmaceuticals LLCFlarex | $34,328 | $1,51312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Westlake
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
- Christopher RiemannCincinnati$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.